美股新聞 標題聯播 · 近 24 小時 250 則 · 24 個來源 · 最新 9/20 08:30
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · AXSM近 30 天 19 則 · 第 1 / 1 頁
- Axsome Sees AUVELITY Prescriptions Accelerate as Alzheimer’s Launch Gains Traction
- Axsome Therapeutics (AXSM) Stock Looks Undervalued As Its 5 Year 7x Run Continues
- Is Axsome Therapeutics’ (AXSM) New CNS Data Enough To Reinforce Its Neuropsychiatric Portfolio Story?
- Axsome Therapeutics Highlights Auvelity Growth, Pipeline Progress at H.C. Wainwright Conference
- Axsome Therapeutics (AXSM) Reported New Clinical Data In Depression And Alzheimer’s Agitation
- Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?
- Axsome Therapeutics vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026?
- Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
- Is Axsome Therapeutics a Buy on the Dip?
- Axsome Therapeutics Presents Ten Posters Exemplifying its Innovative Psychiatry and Neurology Portfolio at Psych Congress 2026
- AXSM Jumps 6% As Mizuho Calls Auvelity’s Alzheimer’s Launch A ‘Strong Start’
- Axsome Therapeutics vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
- Axsome Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
- Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?
- Axsome Therapeutics to Participate in Upcoming Investor Conferences
- Axsome Begins Phase III Study on AXS-05 for Smoking Cessation
- Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
- Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
- Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run
- Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。